Press release

Datesort ascending Press release
27/07/2017 Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA
29/06/2017 Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference
20/06/2017 Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models
06/06/2017 Inventiva to Present at the Jefferies 2017 Global Healthcare Conference
31/05/2017 Résultat des votes de l’Assemblée Générale du 29 mai 2017 (Only in french)
30/05/2017 Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board
15/05/2017 Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337
20/04/2017 Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)
10/04/2017 Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)
27/03/2017 Inventiva: acceleration of the clinical development activities and consolidation of the financial position in 2016
17/03/2017 Inventiva Announces the Implementation of a Liquidity Contract with Oddo & Cie (only in french)
17/03/2017 Inventiva’s confirms the success of its IPO. Over-allotment option partially exercised
14/02/2017 Inventiva raises €48 million in a successful initial public offering on Euronext Paris
02/02/2017 Inventiva launches its initial public offering on the regulated market of Euronext Paris
13/01/2017 Inventiva files an update to its document de base with a view to its initial public offering
03/01/2017 Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
19/09/2016 Inventiva Announces Receipt of €2.3 million in Grant Funding for YAP/TEAD Protein Research Program
11/07/2016 Inventiva announces the registration of its IPO document de base
31/05/2016 Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
25/02/2016 Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress